bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on BLUE. Barclays cut their target price on shares of bluebird bio from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Friday. Robert W. Baird cut their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and decreased their target price for the company from $3.00 to $0.50 in a research note on Friday. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. cut shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.03.

bluebird bio Trading Down 11.5 %

Shares of BLUE stock opened at $0.32 on Monday. The stock has a market cap of $62.21 million, a P/E ratio of -0.17 and a beta of 0.76. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. bluebird bio has a fifty-two week low of $0.32 and a fifty-two week high of $5.53. The business has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.78.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The business had revenue of $18.57 million for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 238.15%. On average, analysts forecast that bluebird bio will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BLUE. Allegheny Financial Group LTD bought a new position in bluebird bio during the second quarter worth $25,000. Verition Fund Management LLC acquired a new stake in shares of bluebird bio during the 3rd quarter worth about $42,000. Bayesian Capital Management LP bought a new position in bluebird bio during the 1st quarter valued at about $52,000. SG Americas Securities LLC boosted its stake in bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 74,185 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 29,113 shares in the last quarter. 87.43% of the stock is owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.